Cargando…

Tamoxifen associated to the conservative CKD treatment promoted additional antifibrotic effects on experimental hypertensive nephrosclerosis

CKD progression depends on the activation of an intricate set of hemodynamic and inflammatory mechanisms, promoting renal leukocyte infiltration, inflammation and fibrosis, leading to renal function loss. There are currently no specific drugs to detain renal fibrogenesis, which is a common end-point...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fanelli, Camilla, Francini, Ana L. R., Celestrino, Giovanna A., Teles, Flávio, Barbosa, Ana P., Noda, Paloma, Iannuzzi, Leandro R., Guzzo, Cristiane R., Ornellas, Felipe M., Noronha, Irene L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460450/ https://www.ncbi.nlm.nih.gov/pubmed/37633958 http://dx.doi.org/10.1038/s41598-023-39299-9

Ejemplares similares

Synergic Renoprotective Effects of Combined ASC Therapy with RAAS Blockade in Experimental Advanced CKD
por: Maires, Marina P. C., et al.
Publicado: (2022)

Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis
por: Momoki, Kumiko, et al.
Publicado: (2017)

Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race
por: Hughson, Michael D., et al.
Publicado: (2014)

Influence of variability in the cyclooxygenase pathway on cardiovascular outcomes of nephrosclerosis patients
por: González, Luz M., et al.
Publicado: (2023)

Adolescent-onset TAFRO Syndrome with Malignant Nephrosclerosis-like Lesions
por: Nakayama, Yuki, et al.
Publicado: (2022)

Investigation into the underlying molecular mechanisms of hypertensive nephrosclerosis using bioinformatics analyses
por: Liu, Tianlong, et al.
Publicado: (2018)

Bone Morphogenetic Protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis
por: Bramlage, Carsten P, et al.
Publicado: (2010)

Effect of Intensive Blood Pressure Control on Cardiovascular Remodeling in Hypertensive Patients with Nephrosclerosis
por: Randall, Otelio, et al.
Publicado: (2013)

Tag-SNPs in Phospholipase-Related Genes Modify the Susceptibility to Nephrosclerosis and its Associated Cardiovascular Risk
por: González, Luz M., et al.
Publicado: (2022)

Tamoxifen and bone morphogenic protein-7 modulate fibrosis and inflammation in the peritoneal fibrosis model developed in uremic rats
por: Silva, Filipe M. O., et al.
Publicado: (2019)

Comparative analysis of hypertensive nephrosclerosis in animal models of hypertension and its relevance to human pathology. Glomerulopathy
por: Gutsol, Alex A., et al.
Publicado: (2022)

Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis
por: Øvrehus, Marius A., et al.
Publicado: (2019)

Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients
por: González, Luz María, et al.
Publicado: (2021)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine, Methionine, and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis
por: Øvrehus, Marius A., et al.
Publicado: (2018)

Serum Potassium Predicts Time to Blood Pressure Response Among African-Americans with Hypertensive Nephrosclerosis
por: Bhalla, Meeta, et al.
Publicado: (2012)

Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis
por: Sumida, Keiichi, et al.
Publicado: (2016)

Antifibrotics in India
por: Dhar, Raja
Publicado: (2019)

Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats
por: Silva, Everidiene K. V. B., et al.
Publicado: (2022)

Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study
por: Liang, Shaoshan, et al.
Publicado: (2016)

Comparison of 6 equations for estimating glomerular filtration rate in a Chinese benign hypertensive nephrosclerosis population
por: Ke, Guibao, et al.
Publicado: (2021)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

The Elusive Antifibrotic Macrophage
por: Adhyatmika, Adhyatmika, et al.
Publicado: (2015)

The Renal Protective Effect of Jiangya Tongluo Formula, through Regulation of Adrenomedullin and Angiotensin II, in Rats with Hypertensive Nephrosclerosis
por: Han, Lin, et al.
Publicado: (2015)

Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study
por: Kurumatani, Hajimu, et al.
Publicado: (2021)

Endothelial-derived complement factor D contributes to endothelial dysfunction in malignant nephrosclerosis via local complement activation
por: Wang, Zheng, et al.
Publicado: (2023)

SARS-CoV-2 Nucleocapsid Protein is Associated With Lower Testosterone Levels: An Experimental Study
por: Lucio Carrasco, Caio Henrique, et al.
Publicado: (2022)

Deciphering the Antifibrotic Property of Metformin
por: Septembre-Malaterre, Axelle, et al.
Publicado: (2022)

Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites
por: Miguel-Carrasco, José Luis, et al.
Publicado: (2017)

Comments on “Supervised Exercise Intervention and Overall Activity in CKD” by Pike et al.
por: Andrade, Francini Porcher, et al.
Publicado: (2020)

Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map
por: Abe, Masanori, et al.
Publicado: (2016)

Clinicopathological discordance in biopsy-proven nephrosclerosis: a nationwide cross-sectional study of the Japan Renal Biopsy Registry (J-RBR)
por: Sumida, Keiichi, et al.
Publicado: (2021)

Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
por: Murray, Lynne A., et al.
Publicado: (2017)

Antifibrotic Activity of Acylated and Unacylated Ghrelin
por: Angelino, Elia, et al.
Publicado: (2015)

Antifibrotic function of cGKI in the kidney
por: Schlossmann, Jens, et al.
Publicado: (2015)

Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016)

Antifibrotic therapy to normalize the tumor microenvironment
por: Hauge, Anette, et al.
Publicado: (2020)

Antifibrotic Therapies: Will We Ever Get There?
por: Thompson, Alexander James, et al.
Publicado: (2010)

PPARG as therapeutic target for antifibrotic therapy
por: Ghallab, Ahmed, et al.
Publicado: (2020)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5nvgj824nd1gktbkmh3pv7jvte